Day: July 6, 2023

Second Quarter Bookings by SPS Approximately $4,500,000 June Bookings From Power Group Approximate $1,000,000 HAUPPAUGE, N.Y., July 06, 2023 (GLOBE NEWSWIRE) — Orbit International Corp. (OTC Expert Market:ORBT), an electronics manufacturer and software solution provider, today announced that bookings from its Simulator Product Solutions LLC subsidiary (“SPS”) for the month of June 2023 were in excess of $3,000,000 and its second quarter bookings were approximately $4,500,000. Deliveries for the June 2023 orders are expected to commence in the third quarter of 2023 and are expected to continue through the second quarter of 2024. In addition, the Company also announced that bookings for its Power Group (“OPG”) for the month of June were approximately $1,000,000. Deliveries for these orders have already commenced and are expected...

Conduent also recognized among the Best CEOs for Diversity and Women FLORHAM PARK, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, today announced it has been honored by Comparably with a Best Leadership Team award. Conduent was recognized based on employee ratings of its leadership team including its CEO, executives and direct managers. “Our associates around the world have worked hard to build a culture that we all can be proud of and the Comparably awards reflect those efforts,” said Cliff Skelton, President and Chief Executive Officer, Conduent. “This recognition is based on the ratings and personal views of our employees and acknowledges the commitment and dedication of Conduent leaders at every level who give their all every day.” Conduent’s...

Highlights:Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the pharmacokinetics and tolerability of IHL-42X The trial will include 116 participants at CMAX Clinical Research in South Australia and will be managed by Novotech Data from the clinical trial will be a critical component of future marketing submissions for IHL-42X for treatment of OSA The trial will be conducted in parallel to the IND opening and pivotal Phase 2/3 clinical trial OSA is highly prevalent, affecting approximately 30 million adults in the United States alone and there are no registered prescription drugs available to patients for the treatment of OSA The design of the BA/BE trial is consistent with FDA recommendations as part of the required...

JOHNS CREEK, Ga., July 06, 2023 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: Ebix), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare, and e-learning industries, today provided a strategic update, detailing the multiple paths it is pursuing to achieve the stated aspirational goal of being a debt-free company in 2023. The Company declared a multi-pronged plan towards achieving the aspirational goal –The Company announced that it is progressing forward diligently with its plan to complete an initial public offering (IPO) of its EbixCash subsidiary in India. In accordance with the directions and regulations of the Indian regulators, EbixCash intends to announce a IPO listing date publicly as soon as it has the requisite approvals in place. Ebix also announced that it...

In relation to Landsbankinn’s covered bond auction yesterday, was a covered bond exchange offering where holders of the series LBANK CB 23 could sell the covered bonds in the series against covered bonds bought in the auction at a predefined clean price of 98.663. The covered bond exchange offering results in Landsbankinn buying ISK 1,980m in the series LBANK CB 23. Settlement will take place on 12 July 2023.

Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th Annual CAR-TCR Summit WORCESTER, Mass., July 06, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that members of its management team will participate in the 2ndIn Vivo Engineering of Therapeutic Cells Summit, scheduled to take place from July 10-12, 2023, and the 8th Annual CAR-TCR Summit, scheduled to take place from August 29 – September 1, 2023, both in Boston, MA. Event details are as follows: 2ndIn Vivo Engineering of Therapeutic Cells Summit Date & Time: July 11, 2023, at 11:00...

SANTA CLARA, Calif., July 06, 2023 (GLOBE NEWSWIRE) — SiTime Corporation (Nasdaq: SITM), the precision timing company, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023, after market close. Rajesh Vashist, SiTime’s chief executive officer, and Art Chadwick, chief financial officer, will broadcast a conference call at 2:00 p.m. Pacific Time to discuss the company’s results. Analysts and investors are invited to join the conference call using the following information: Date: Wednesday, August 2, 2023Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)Live webcast: Click HereRegister for dial-in number: Click Here Advanced registration is required for dial-in participants. Please complete the linked registration form above to receive a dial-in number and dedicated PIN for accessing the conference...